Inhibrx Biosciences INBX
NASDAQ INBX
$98.19 +2.89 (+3.03%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibrx Biosciences (INBX) EBITDA (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) posted EBITDA of -$31.63 million for Q2 2026, compared with -$26.73 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) EBITDA (2023 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EBITDA at Inhibrx Biosciences was -$121.94 million; for FY2025, it was -$132.54 million.

  • In prior years, Inhibrx Biosciences' EBITDA was -$329.16 million in FY2024 and -$218.03 million in FY2023.
  • Quarterly EBITDA has run from a low of -$160.42 million in Q2 2024 to a high of -$26.73 million in Q2 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 12.29 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 9.10 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 8.33 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 999.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 5.09 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 4.63 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -9.70 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 5.89 Bn
10 Inhibrx Biosciences 1.54 Bn 937.90 Mn - -31.63 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -31.63 Mn
Dec 31, 2025 -29.72 Mn
Sep 30, 2025 -32.59 Mn
Jun 30, 2025 -26.10 Mn
Mar 31, 2025 -41.69 Mn
Dec 31, 2024 -49.24 Mn
Sep 30, 2024 -46.04 Mn
Jun 30, 2024 -159.60 Mn
Mar 31, 2024 -72.22 Mn
Dec 31, 2023 -86.74 Mn
Sep 30, 2023 -44.28 Mn
Jun 30, 2023 -41.04 Mn
API Access

Inhibrx Biosciences EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=INBX&period=max&api_key=YOUR_API_KEY